Buchumschlag

Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance

Our study elucidates the role of FOXP1 in chemoresistance in small cell lung cancer(SCLC). FOXP1 enhances chemoresistance by regulating SP8 expression through its super-enhancer (SP8-SE), with SP8 mediating resistance via the homologous recombination repair (HRR) pathway. We also discovered that FOX...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tang, Yichun (VerfasserIn) , Niu, Yuchun (VerfasserIn) , Chen, Yi (VerfasserIn) , Zhou, Xuyang (VerfasserIn) , Hu, Yueyang (VerfasserIn) , Sun, Lei (VerfasserIn) , Xiong, Yan (VerfasserIn) , Xu, Yue (VerfasserIn) , Wang, Qiongyao (VerfasserIn) , Wang, Yu (VerfasserIn) , Guo, Linlang (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 13 March 2025
In: Communications biology
Year: 2025, Jahrgang: 8, Pages: 1-15
ISSN:2399-3642
DOI:10.1038/s42003-025-07804-7
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s42003-025-07804-7
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s42003-025-07804-7
Volltext
Verfasserangaben:Yichun Tang, Yuchun Niu, Yi Chen, Xuyang Zhou, Yueyang Hu, Lei Sun, Yan Xiong, Yue Xu, Qiongyao Wang, Yu Wang & Linlang Guo
Beschreibung
Zusammenfassung:Our study elucidates the role of FOXP1 in chemoresistance in small cell lung cancer(SCLC). FOXP1 enhances chemoresistance by regulating SP8 expression through its super-enhancer (SP8-SE), with SP8 mediating resistance via the homologous recombination repair (HRR) pathway. We also discovered that FOXP1 forms punctate nuclear structures indicative of liquid-liquid phase separation, crucial for its transcriptional regulation. Targeting the FOXP1-SP8-HR axis with BRD4 and PARP inhibitors showed synergistic effects in reducing tumor growth in vitro and in patient-derived xenograft models. These findings identify FOXP1 as a critical mediator and marker of chemoresistance in SCLC, providing a foundation for developing targeted therapies to overcome this resistance.
Beschreibung:Gesehen am 14.08.2025
Beschreibung:Online Resource
ISSN:2399-3642
DOI:10.1038/s42003-025-07804-7

Ähnliche Einträge